
|Articles|February 1, 2005
Studies confirm utility of fixed-combination glaucoma drug
New Orleans—Twice-daily administration of a fixed-combination product containing brimonidine 0.2% plus timolol 0.5% (Combigan, Allergan Inc.) safely and effectively lowers IOP, according to the pooled results of two 12-month, randomized, double-masked, phase III studies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Q&A: As DMEI turns 50, R. Michael Siatkowski, MD, MBA, looks to the future
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week
5

















































.png)


